Symptomatic malignant ascites drainage with a patient-controlled vascular catheter: interim analysis of safety and patient-reported outcomes

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10494458" target="_blank" >RIV/00179906:_____/25:10494458 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/25:10494458 RIV/00216208:11150/25:10494458 RIV/00064165:_____/25:10494458

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=WV99-y_eYh" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=WV99-y_eYh</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00520-025-09265-4" target="_blank" >10.1007/s00520-025-09265-4</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Symptomatic malignant ascites drainage with a patient-controlled vascular catheter: interim analysis of safety and patient-reported outcomes

Popis výsledku v původním jazyce

Malignant ascites (MA) and repeated paracentesis can impair a patient&apos;s quality of life (QOL). The aim was to perform an interim analysis of safety and changes in patients&apos; QOL in an ongoing prospective, multicentre (conducted within the Central and Eastern European Gynaecologic Oncology Group (CEEGOG)) trial on symptomatic MA drainage with a patient-controlled central vascular catheter (CVC) inserted into the abdominal cavity. CVC (14-Ga) was inserted into the abdominal cavity of patients with symptomatic MA, and drainage was controlled by patients at home. The rate and quality of complications were classified according to Common Terminology Criteria for Adverse Events Version 5.0. QOL was evaluated before and 10-14 days after/during drainage with standardized QLQ-C15-PAL, SGA, and FACIT-TS-G questionnaires. Wilcoxon and Chi-squared tests were used. Among 113 recruited patients (2015-2022), seven patients experienced complications (6.2%), and there was one patient with a serious adverse event (death on the 9th day after catheter insertion, classified as not related to the intervention). Adverse events included local infection (n = 2) (resolved after oral antibiotics), catheter obstruction (n = 2), catheter self-removal (n = 2) (re-insertion performed), and nausea (n = 1). When comparing the assessment before and after/during drainage, we found the significantly better global QOL (mean 31.8 vs. 47.8, p &lt; 0.001), improvement in physical (52.6 vs. 64.4, p &lt; 0.001) and emotional functioning (50.7 vs. 65.4, p &lt; 0.001); symptoms were significantly less intense: fatigue (66.7 vs. 50.9, p &lt; 0.001), nausea and vomiting (37.8 vs. 21.4, p &lt; 0.001), pain (53.9 vs. 34.1, p &lt; 0.001), dyspnoea (48.5 vs. 22.3, p &lt; 0.001), insomnia (49.1 vs. 34.3, p &lt; 0.001), appetite loss (56.3 vs. 40.3, p &lt; 0.001), and constipation (31.0 vs. 25.2, p = 0.007), and more patients had no pain on eating (71.3% vs. 82.9%, p = 0.04). Most patients (78%) were satisfied, 83% would recommend the procedure to others, and 90% would choose intervention again. The interim analysis provided data on the safety and improvement of patients&apos; QOL after MA drainage via patient-controlled CVC inserted into the abdominal cavity, thus justifying the continuation of recruitment for the main trial without changes in the protocol.

Název v anglickém jazyce

Symptomatic malignant ascites drainage with a patient-controlled vascular catheter: interim analysis of safety and patient-reported outcomes

Popis výsledku anglicky

Malignant ascites (MA) and repeated paracentesis can impair a patient&apos;s quality of life (QOL). The aim was to perform an interim analysis of safety and changes in patients&apos; QOL in an ongoing prospective, multicentre (conducted within the Central and Eastern European Gynaecologic Oncology Group (CEEGOG)) trial on symptomatic MA drainage with a patient-controlled central vascular catheter (CVC) inserted into the abdominal cavity. CVC (14-Ga) was inserted into the abdominal cavity of patients with symptomatic MA, and drainage was controlled by patients at home. The rate and quality of complications were classified according to Common Terminology Criteria for Adverse Events Version 5.0. QOL was evaluated before and 10-14 days after/during drainage with standardized QLQ-C15-PAL, SGA, and FACIT-TS-G questionnaires. Wilcoxon and Chi-squared tests were used. Among 113 recruited patients (2015-2022), seven patients experienced complications (6.2%), and there was one patient with a serious adverse event (death on the 9th day after catheter insertion, classified as not related to the intervention). Adverse events included local infection (n = 2) (resolved after oral antibiotics), catheter obstruction (n = 2), catheter self-removal (n = 2) (re-insertion performed), and nausea (n = 1). When comparing the assessment before and after/during drainage, we found the significantly better global QOL (mean 31.8 vs. 47.8, p &lt; 0.001), improvement in physical (52.6 vs. 64.4, p &lt; 0.001) and emotional functioning (50.7 vs. 65.4, p &lt; 0.001); symptoms were significantly less intense: fatigue (66.7 vs. 50.9, p &lt; 0.001), nausea and vomiting (37.8 vs. 21.4, p &lt; 0.001), pain (53.9 vs. 34.1, p &lt; 0.001), dyspnoea (48.5 vs. 22.3, p &lt; 0.001), insomnia (49.1 vs. 34.3, p &lt; 0.001), appetite loss (56.3 vs. 40.3, p &lt; 0.001), and constipation (31.0 vs. 25.2, p = 0.007), and more patients had no pain on eating (71.3% vs. 82.9%, p = 0.04). Most patients (78%) were satisfied, 83% would recommend the procedure to others, and 90% would choose intervention again. The interim analysis provided data on the safety and improvement of patients&apos; QOL after MA drainage via patient-controlled CVC inserted into the abdominal cavity, thus justifying the continuation of recruitment for the main trial without changes in the protocol.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Supportive Care in Cancer

ISSN

0941-4355

e-ISSN

1433-7339

Svazek periodika

33

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

202

Kód UT WoS článku

001426610600002

EID výsledku v databázi Scopus

2-s2.0-85218672215